Switching to Progressively Reduced Nicotine Content Cigarettes in Smokers With Low Socioeconomic Status: A Double-Blind Randomized Clinical Trial.
Journal
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
ISSN: 1469-994X
Titre abrégé: Nicotine Tob Res
Pays: England
ID NLM: 9815751
Informations de publication
Date de publication:
24 05 2021
24 05 2021
Historique:
received:
17
04
2020
accepted:
24
11
2020
pubmed:
30
11
2020
medline:
16
10
2021
entrez:
29
11
2020
Statut:
ppublish
Résumé
The Food and Drug Administration issued an advanced notice of proposed rulemaking for setting a product standard for nicotine levels in cigarettes, with an emphasis on minimally or non-addicting very low nicotine content (VLNC). A 33 week, two-arm, double-blind randomized trial conducted in Hershey, Pennsylvania, USA and Washington, DC, USA included adult daily cigarette smokers (≥5 cigarettes per day) with less than a college degree, and who had no plans to quit within the next six months. Participants were randomized to either reduced nicotine content (RNC) study cigarettes tapered every three weeks to a final VLNC (0.2 mg/cigarette) for six weeks or to usual nicotine content (UNC) study cigarettes (11.6 mg/cigarette). Outcomes included acceptability of study cigarettes measured by attrition (primary outcome), compliance, reduction in cigarette dependence and tobacco biomarkers, and post-intervention cessation. The RNC (n = 122) versus UNC (n = 123) group had higher attrition (adjusted Hazard Ratio 3.4; 95% confidence interval [CI] 1.99 to 5.81). At the end of the intervention, cotinine levels were 50% lower in the RNC group (mean group difference -137 ng/mL; 95% CI -172, -102). The RNC group smoked fewer CPD (-4.1; 95% CI -6.44, -1.75) and had lower carbon monoxide levels (-4.0 ppm; 95% CI -7.7, -0.4). Forty seven percent (29/62) of the RNC group were biochemically-confirmed compliant with smoking VLNC cigarettes (mean cotinine = 8.9 ng/ml). At three month follow-up, only compliant VLNC smokers quit with an assisted quit attempt (N = 6/22, 27%). This study supports a VLNC standard in cigarettes. Differential dropout and noncompliance indicate some smokers had difficulty transitioning to cigarettes with reduced nicotine. These smokers will benefit from supplemental nicotine in medicinal or noncombustible tobacco products if a nicotine reduction standard is established. Other smokers successfully transitioned to very low nicotine content cigarettes exclusively and substantially reduced their exposure to nicotine.
Identifiants
pubmed: 33249498
pii: 6010042
doi: 10.1093/ntr/ntaa247
pmc: PMC8150128
doi:
Substances chimiques
Nicotine
6M3C89ZY6R
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
992-1001Subventions
Organisme : NIDA NIH HHS
ID : P50 DA036107
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Addiction. 2017 Jan;112(1):156-167
pubmed: 27614097
Nicotine Tob Res. 2017 Oct 01;19(10):1149-1154
pubmed: 28003507
N Engl J Med. 2015 Oct;373(14):1340-9
pubmed: 26422724
Nicotine Tob Res. 2020 Feb 6;22(2):273-279
pubmed: 30892637
Nicotine Tob Res. 2005 Feb;7(1):157-61
pubmed: 15804688
Prev Med. 2018 Dec;117:24-29
pubmed: 29626556
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2479-85
pubmed: 18006940
Nicotine Tob Res. 2015 Feb;17(2):186-92
pubmed: 25332459
Contemp Clin Trials Commun. 2018 May 05;11:69-74
pubmed: 30023460
Nicotine Tob Res. 2001 Feb;3(1):7-16
pubmed: 11260806
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
N Engl J Med. 1994 Jul 14;331(2):123-5
pubmed: 7818638
Exp Clin Psychopharmacol. 2018 Jun;26(3):223-232
pubmed: 29504780
J Ethn Subst Abuse. 2020 Jan-Mar;19(1):133-150
pubmed: 30265848
Addiction. 2010 Feb;105(2):343-55
pubmed: 20078491
Addiction. 2017 Jun;112(6):1095-1103
pubmed: 28107596
N Engl J Med. 2017 Sep 21;377(12):1111-1114
pubmed: 28813211
BMC Public Health. 2017 Jan 19;17(1):100
pubmed: 28103841
Arch Gen Psychiatry. 1986 Mar;43(3):289-94
pubmed: 3954551
Tob Control. 2010 Oct;19(5):e1-10
pubmed: 20876072
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1125-33
pubmed: 27197288
Trials. 2017 Jul 03;18(1):300
pubmed: 28673312
Ann Intern Med. 2017 Nov 21;167(10):736-737
pubmed: 28806818
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
Drug Alcohol Depend. 2017 Apr 01;173:99-106
pubmed: 28214392
Tob Regul Sci. 2017 Dec 1;3(1):81-94
pubmed: 28220149
Tob Regul Sci. 2018 Jan;4(1):573-585
pubmed: 30662929
JAMA Psychiatry. 2017 Oct 1;74(10):1056-1064
pubmed: 28832876
Tob Regul Sci. 2016;2(2):94-105
pubmed: 26779559
Ann N Y Acad Sci. 2012 Feb;1248:107-23
pubmed: 22092035
Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):331-5
pubmed: 25416718
Prev Med. 2018 Dec;117:5-7
pubmed: 29944901
Schizophr Bull. 2009 Jul;35(4):775-88
pubmed: 18303093
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2032-40
pubmed: 25150282
Nicotine Tob Res. 2010 Oct;12 Suppl:S20-33
pubmed: 20889477
MMWR Morb Mortal Wkly Rep. 2018 Nov 09;67(44):1225-1232
pubmed: 30408019
Am J Epidemiol. 2011 Aug 1;174(3):253-60
pubmed: 21749974
Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):761-9
pubmed: 22354905
JAMA. 2018 Sep 4;320(9):880-891
pubmed: 30193275
Nicotine Tob Res. 2019 Dec 23;21(Suppl 1):S133-S144
pubmed: 31867659